Tech Company Inital Public Offerings
Adagio Therapeutics IPO
Headquartered in Waltham, Adagio Therapeutics is now a public company.
Transaction Overview
Company Name
Announced On
8/6/2021
Transaction Type
IPO
Amount
$309,400,000
Proceeds Purpose
The company will use the IPO proceeds to fund clinical development, manufacturing supply and initial commercialization costs for ADG20. Proceeds will also be used for working capital and other general corporate purposes, including development of additional programs in our pipeline.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
303 Wyman St. 300
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Undisclosed
Website
Email Address
Overview
Adagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses. We believe our antibodies will match or exceed the potency and coverage of conventional SARS-CoV-2 antibody programs, and can be used as both therapeutic and durable prophylactic treatments.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tillman Gerngross
Chief Financial Officer
Jane Henderson
Chief Medical Officer
Lynn Connolly
Chief Operating Officer
Halley Gilbert
Chief Scientific Officer
Laura Walker
Chief Technical Officer
Becky Dabora
VP - Bus. Development
Ellie Hershberger
VP - Bus. Development
Eric Kimble
Browse more venture capital transactions:
Prev: 8/6/2021: Bluecore venture capital transaction
Next: 8/6/2021: Octane Lending venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs